» Articles » PMID: 38410229

Sinensetin Suppresses Breast Cancer Cell Progression Via Wnt/β-catenin Pathway Inhibition

Overview
Specialty Oncology
Date 2024 Feb 27
PMID 38410229
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although there are many treatments for breast cancer, such as surgery, radiotherapy, chemotherapy, estrogen receptor antagonists, immune checkpoint inhibitors and so on. However, safer and more effective therapeutic drugs for breast cancer are needed. Sinensetin, a safer therapeutic drugs, come from citrus species and medicinal plants used in traditional medicine, while its role and underlying mechanism in breast cancer remain unclear. Our study aimed to investigate the role and mechanism of sinensetin in breast cancer.

Methods: Cell Counting Kit-8 (CCK-8) was used to determine the safe concentration of sinensetin in MCF-10A, MCF7 and MDA-MB-231 cells; 120 μM sinensetin was used in subsequent experiments. Real time polymerase chain reaction (RT-PCR), Western blotting, Terminal Deoxynucleotidyl Transferase mediated dUTP Nick-End Labeling (TUNEL) apoptosis assay, Transwell invasion assay and Clone formation assay were used in this study to determine cell viability, mRNA expression, protein levels, apoptosis, proliferation, invasion and so on.

Results: Herein, our results showed that 120 μM sinensetin suppressed the cell viability and promoted apoptosis of MCF7 and MDA-MB-231 cells. Treatment with 120 µM sinensetin for 24 h showed no significant toxicity to normal mammary cells; 120 μM sinensetin decreased cell proliferation, invasion, and epithelial-mesenchymal transition (EMT), and downregulated β-catenin, lymphatic enhancing factor 1 (LEF1), T-cell factor (TCF) 1/TCF7, and TCF3/TCF7L1 expression in MCF7 and MDA-MB-231 cells. The Wnt agonist SKL2001 reversed the inhibitory effect of sinensetin on cell survival, metastasis, and EMT. Sinensetin-induced downregulation of β-catenin, LEF1, and TCF1/TCF7 expression were upregulated by SKL2001 in MCF7 and MDA-MB-231 cells.

Conclusions: In summary, sinensetin suppressed the metastasis of breast cancer cell via inhibition of Wnt/β-catenin pathway and there were no adverse effects on normal breast cells. Our study confirmed the role of sinensetin in breast cancer cells and provided a better understanding of the underlying mechanism.

Citing Articles

LncRNA TCL6 regulates miR-876-5p/MYL2 axis to suppress breast cancer progression.

Liu Y, Li H, Chai D, Lian B, Bai Z, Gao Y Transl Oncol. 2025; 53:102210.

PMID: 39874729 PMC: 11810844. DOI: 10.1016/j.tranon.2024.102210.


FNDC1 Facilitates Proliferation, Migration, and Invasion of Breast Cancer Cells Through Modulating Wnt/β-Catenin Pathway.

Fan G, Zhang C Biochem Genet. 2024; .

PMID: 39671143 DOI: 10.1007/s10528-024-10994-0.


Flavonoids of Euphorbia hirta inhibit inflammatory mechanisms via Nrf2 and NF-κB pathways.

Bai X, Li L, Wu Y, Jie B Cell Biochem Biophys. 2024; 83(1):1167-1183.

PMID: 39505796 DOI: 10.1007/s12013-024-01551-y.


A-to-I-edited miR-1251-5p restrains tumor growth and metastasis in lung adenocarcinoma through regulating TCF7-mediated Wnt signaling pathway.

Xu S, Zhou G, He Q, Ding J, Liu X, Cheng Y Discov Oncol. 2024; 15(1):587.

PMID: 39446175 PMC: 11502620. DOI: 10.1007/s12672-024-01462-7.


Sinensetin Inhibits Angiogenesis in Lung Adenocarcinoma via the miR-374c-5p/VEGF-A/VEGFR-2/AKT Axis.

Ji T, Ye L, Xi E, Liu Y, Wang X, Wang S Cell Biochem Biophys. 2024; 82(3):2413-2425.

PMID: 39030333 DOI: 10.1007/s12013-024-01352-3.

References
1.
Munoz J, Perez-Moreno P, Perez Y, Calaf G . The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application. Diagnostics (Basel). 2023; 13(19). PMC: 10572677. DOI: 10.3390/diagnostics13193072. View

2.
Liao S, Chen H, Liu M, Gan L, Li C, Zhang W . Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway. Aging (Albany NY). 2020; 12(2):1527-1544. PMC: 7053619. DOI: 10.18632/aging.102698. View

3.
Torello C, Alvarez M, Saad S . Polyphenolic Flavonoid Compound Quercetin Effects in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Molecules. 2021; 26(19). PMC: 8510366. DOI: 10.3390/molecules26195781. View

4.
Mukherjee N, Panda C . Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons. Clin Breast Cancer. 2020; 20(5):361-370. DOI: 10.1016/j.clbc.2020.04.004. View

5.
Moon S, Choi H, Kye Y, Jeong G, Kim H, Myung J . CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer. Cancers (Basel). 2023; 15(4). PMC: 9954024. DOI: 10.3390/cancers15041168. View